ClinicalTrials.gg
RecruitingNCT02246634SERENADEUpdated Oct 17, 2024

Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)

An interventional study of Diffusion Weighted MRI scan in Colorectal Neoplasms, Neoplasm Metastases and Hepatic Neoplasms, sponsored by Imperial College London. Recruiting at 13 sites in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Imperial College London · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Aug 2014; still recruiting 12 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
282
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Colorectal Neoplasms by Imperial College London — 6 open to participants now, 6 under way, none of them phase 3. Colorectal Neoplasms · Imperial College London.

Started
2014
with 1 other
No phase
4 of 13
3 open now
Registered
6th of 13
by date

Among the 13 studies in Colorectal Neoplasms by Imperial College London, this one is one of 2 that started in 2014, is one of 4 with no phase, and was the 6th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

6 of the 13 studies in Colorectal Neoplasms by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Colorectal Neoplasms by Imperial College London, or all of them as a file.
02

Study summary

Eligible patients with high risk colorectal malignancy (T3/4, spread greater than 5mm, EMVI positive) will have additional surveillance of breath hold T1, T2 and DW-MRIs (no IV contrast) post surgery six monthly for three years.

Findings of liver MRIs as reported by radiology PI will be shared with their local MDT who make decisions as appropriate, including the management of any identified liver metastases, according to local protocol.

Read the detailed description

A phase II multicentre, interventional study to determine if additional staging at diagnosis with liver DW-MRI will diagnose more synchronous metastases than CT alone in patients with high risk colorectal cancer. Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local policy.

03

Conditions studied

  • Colorectal Neoplasms
  • Neoplasm Metastases
  • Hepatic Neoplasms

Keywords

  • Colorectal Neoplasms
  • Neoplasm Metastases
  • Magnetic Resonance Imaging
  • Diffusion Weighted MRI
  • Hepatic Neoplasms
  • Tumors
  • Neoplasms, Rectal
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a high risk primary colorectal
  2. Have a negative CT or includes no confirmatory evidence of liver
  3. Is able to undergo treatment if liver metastasis is found
  4. Have provided written to participate in the study
  5. Be aged 16 years or over

Exclusion criteria

Exclusion Criteria:

  1. Have had a previous colorectal
  2. Have disease
  3. Have a synchronous second malignancy
  4. Are for MRI
  5. Has a T3b or below low rectal tumour without EMVI or N1c
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
282 participants (estimated)

Study arms

  • Experimental
    Diffusion Weighted MRI scan

    Patients who are enrolled in the study will undergo an additional diffusion weighted MRI (T2W, DWI and ADC sequences) of the liver.

    Other: Diffusion Weighted MRI scan

Interventions

  • OtherDiffusion Weighted MRI scan

    Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.

06

What researchers measure

Primary outcomes

  1. Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.

    Proportion of additional patients diagnosed with liver metastases on DW MRI compared with CT.

    Time frame: 5 years after last recruit (end of trial)

Secondary outcomes

  1. To compare the baseline risk factors of the primary tumour against the timing and pattern of metastatic disease relapse in the liver.

    % of patients diagnosed with liver metastases according to known prognostic risk factors

    Time frame: 5 years after last recruit (end of trial)

  2. To determine the sensitivity and specificity of DW-MRI as a screening method for liver lesions in patients with high risk colorectal cancer.

    % lesions suspected as metastatic on DW MRI confirmed by subsequent 'gold standard' of contrast enhanced MRI and/or surgical resection, and/or progressive enlargement of the lesion.

    Time frame: 5 years after last recruit (end of trial)

  3. To describe the cancer specific disease free survival and overall survival outcomes in patients with and without liver metastases.

    Survival and recurrence outcomes according to presence or absence of liver metastases

    Time frame: 6mth, 12mth, 18mth, 2yr, 3yr

  4. To characterise the patients diagnosed through screening with liver metastasis in the SERENADE study using the Fong criteria.

    Fong score of all patients with liver metastases

    Time frame: 5 years after last recruit (end of trial)

  5. To describe the impact of MR screening on treatment received by patients who are diagnosed with liver metastases.

    Proportion of patients undergoing curative treatment and methods of treatment

    Time frame: 5 years after last recruit (end of trial)

07

Study locations

12 of 13 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2014 (actual). Primary completion is estimated for Dec 2026, 148 months after the start.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 148 months is above that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2014
First posted
Sep 23, 2014
StartActual
Aug 2014
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2031
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02246634
Collaborators
Pelican Cancer Foundation
Responsible party
Sponsor
First posted
Sep 23, 2014
Start date
Aug 2014
Primary completion
Dec 2026 (estimated)
Completion
Dec 2031 (estimated)
Last update
Oct 17, 2024

Study contacts

Caroline Martin
Contact
c.martin1@imperial.ac.uk
+44 (0) 7749 655 817
Syvella Ellis
Contact
giclinicaltrials@imperial.ac.uk
+44 (0) 7732 315 234
Gina Brown
principal investigator · Imperial College London

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion